Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.

Jothi M, Nishijo K, Keller C, Mal AK.

Cell Cycle. 2012 Mar 1;11(5):895-908. doi: 10.4161/cc.11.5.19346.

2.

PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis.

Graf Finckenstein F, Shahbazian V, Davicioni E, Ren YX, Anderson MJ.

Oncogene. 2008 Mar 27;27(14):2004-14.

PMID:
17922034
3.

Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells.

Calhabeu F, Hayashi S, Morgan JE, Relaix F, Zammit PS.

Oncogene. 2013 Jan 31;32(5):651-62. doi: 10.1038/onc.2012.73.

PMID:
22710712
4.

Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.

Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y, Yagyu S, Tsubai-Shimizu S, Miyachi M, Iehara T, Hosoi H.

Biochem Biophys Res Commun. 2008 Jan 18;365(3):568-74.

PMID:
18022385
6.

Pax7-FKHR transcriptional activity is enhanced by transcriptionally repressed MyoD.

Olguín HC, Patzlaff NE, Olwin BB.

J Cell Biochem. 2011 May;112(5):1410-7. doi: 10.1002/jcb.23057.

7.
8.

Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.

Jothi M, Mal M, Keller C, Mal AK.

Mol Cancer Ther. 2013 Dec;12(12):2663-74. doi: 10.1158/1535-7163.MCT-13-0277.

10.

PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation.

Charytonowicz E, Matushansky I, Doménech JD, Castillo-Martín M, Ladanyi M, Cordon-Cardo C, Ziman M.

Clin Transl Oncol. 2012 Mar;14(3):197-206.

PMID:
22374423
11.
12.

Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.

Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Laé M, Ladanyi M, Barr FG.

Genes Chromosomes Cancer. 2008 Jun;47(6):510-20. doi: 10.1002/gcc.20554.

PMID:
18335505
13.

High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts.

Xia SJ, Holder DD, Pawel BR, Zhang C, Barr FG.

Am J Pathol. 2009 Dec;175(6):2600-8. doi: 10.2353/ajpath.2009.090192.

14.

Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.

Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS.

Cancer Res. 2010 Aug 15;70(16):6497-508. doi: 10.1158/0008-5472.CAN-10-0582.

15.

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C.

Cancer Res. 2006 May 1;66(9):4742-9.

16.

Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?

Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M.

Cancer Lett. 2009 Jul 8;279(2):126-36. doi: 10.1016/j.canlet.2008.09.039. Review.

PMID:
19008039
17.

cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.

Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9.

18.

Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations.

Ren YX, Finckenstein FG, Abdueva DA, Shahbazian V, Chung B, Weinberg KI, Triche TJ, Shimada H, Anderson MJ.

Cancer Res. 2008 Aug 15;68(16):6587-97. doi: 10.1158/0008-5472.CAN-08-0859.

19.
20.

Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis.

Charytonowicz E, Matushansky I, Castillo-Martin M, Hricik T, Cordon-Cardo C, Ziman M.

Clin Transl Oncol. 2011 Mar;13(3):194-203. doi: 10.1007/s12094-011-0640-y.

PMID:
21421465
Items per page

Supplemental Content

Support Center